These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21907257)

  • 1. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.
    Gee J; Naleway A; Shui I; Baggs J; Yin R; Li R; Kulldorff M; Lewis E; Fireman B; Daley MF; Klein NP; Weintraub ES
    Vaccine; 2011 Oct; 29(46):8279-84. PubMed ID: 21907257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females.
    Yih WK; Greene SK; Zichittella L; Kulldorff M; Baker MA; de Jong JL; Gil-Prieto R; Griffin MR; Jin R; Lin ND; McMahill-Walraven CN; Reidy M; Selvam N; Selvan MS; Nguyen MD
    Vaccine; 2016 Jan; 34(1):172-8. PubMed ID: 26549364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.
    Naleway AL; Crane B; Smith N; Daley MF; Donahue J; Gee J; Greene SK; Harrington T; Jackson LA; Klein NP; Tseng HF; Vellozzi C; Weintraub ES;
    Vaccine; 2016 Jan; 34(1):167-71. PubMed ID: 26549361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events following immunization in Ontario's female school-based HPV program.
    Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
    Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of quadrivalent human papillomavirus vaccine administered routinely to females.
    Klein NP; Hansen J; Chao C; Velicer C; Emery M; Slezak J; Lewis N; Deosaransingh K; Sy L; Ackerson B; Cheetham TC; Liaw KL; Takhar H; Jacobsen SJ
    Arch Pediatr Adolesc Med; 2012 Dec; 166(12):1140-8. PubMed ID: 23027469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine.
    Donahue JG; Kieke BA; Lewis EM; Weintraub ES; Hanson KE; McClure DL; Vickers ER; Gee J; Daley MF; DeStefano F; Hechter RC; Jackson LA; Klein NP; Naleway AL; Nelson JC; Belongia EA
    Pediatrics; 2019 Dec; 144(6):. PubMed ID: 31740498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
    Geier DA; Geier MR
    Immunol Res; 2017 Feb; 65(1):46-54. PubMed ID: 27406735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.
    Moro PL; Zheteyeva Y; Lewis P; Shi J; Yue X; Museru OI; Broder K
    Vaccine; 2015 Jan; 33(4):519-22. PubMed ID: 25500173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.
    Geier DA; Geier MR
    Clin Rheumatol; 2015 Jul; 34(7):1225-31. PubMed ID: 25535199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following HPV vaccination, Alberta 2006-2014.
    Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
    Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.
    Daley MF; Clarke CL; Glanz JM; Xu S; Hambidge SJ; Donahue JG; Nordin JD; Klein NP; Jacobsen SJ; Naleway AL; Jackson ML; Lee G; Duffy J; Weintraub E
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):59-68. PubMed ID: 29148124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.
    Daley MF; Yih WK; Glanz JM; Hambidge SJ; Narwaney KJ; Yin R; Li L; Nelson JC; Nordin JD; Klein NP; Jacobsen SJ; Weintraub E
    Vaccine; 2014 May; 32(25):3019-24. PubMed ID: 24699471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.
    Ojha RP; Jackson BE; Tota JE; Offutt-Powell TN; Singh KP; Bae S
    Hum Vaccin Immunother; 2014; 10(1):232-7. PubMed ID: 24013368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine.
    Chao C; Klein NP; Velicer CM; Sy LS; Slezak JM; Takhar H; Ackerson B; Cheetham TC; Hansen J; Deosaransingh K; Emery M; Liaw KL; Jacobsen SJ
    J Intern Med; 2012 Feb; 271(2):193-203. PubMed ID: 21973261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.
    Kawai AT; Li L; Kulldorff M; Vellozzi C; Weintraub E; Baxter R; Belongia EA; Daley MF; Jacobsen SJ; Naleway A; Nordin JD; Lee GM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):548-53. PubMed ID: 24497128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011.
    Schmidt MA; Gold R; Kurosky SK; Daley MF; Irving SA; Gee J; Naleway AL
    J Adolesc Health; 2013 Nov; 53(5):637-41. PubMed ID: 24138765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
    Vichnin M; Bonanni P; Klein NP; Garland SM; Block SL; Kjaer SK; Sings HL; Perez G; Haupt RM; Saah AJ; Lievano F; Velicer C; Drury R; Kuter BJ
    Pediatr Infect Dis J; 2015 Sep; 34(9):983-91. PubMed ID: 26107345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink.
    Gee J; Sukumaran L; Weintraub E;
    Vaccine; 2017 Oct; 35(43):5756-5758. PubMed ID: 28935469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmasking in an observational vaccine safety study: Using type 2 diabetes mellitus as an example.
    Ackerson BK; Sy LS; Slezak J; Chao CR; Hechter RC; Takhar HS; Jacobsen SJ
    Vaccine; 2015 Nov; 33(46):6224-6. PubMed ID: 26440925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.